Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Stomach diseases].

C Nichita1, F Viani, F Vouillamoz

  • 1Service de Gastro-entérologie et d'Hépatologie, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|February 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Digestive foreign body management].

Revue medicale suisse·2015
Same author

A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer.

Alimentary pharmacology & therapeutics·2014
Same author

[Radiofrequency ablation for Barret's esophagus].

Revue medicale suisse·2013
Same author

[Gastrointestinal neuroendocrine tumors: pleomorphic and often ignored].

Revue medicale suisse·2012
Same author

[Upper gastrointestinal bleeding: usefulness of prognostic scores].

Revue medicale suisse·2011
Same author

[Highlights in gastroenterology and hepatology 2010].

Revue medicale suisse·2011
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

New proton pump inhibitors (PPIs) show faster, longer effectiveness for reflux disease. Endoscopic treatments are declining, and COX-2 inhibitors face reduced use due to cardiac risks.

Area of Science:

  • Gastroenterology
  • Pharmacology

Context:

  • Reflux disease treatment is shifting away from endoscopic procedures.
  • Concerns regarding cardiac side effects have limited the use of COX-2 inhibitors.
  • High-risk patients for NSAID gastro-duodenal toxicity require alternative management strategies.

Purpose:

  • To review current trends in gastrointestinal pharmacotherapy.
  • To highlight advancements in proton pump inhibitor (PPI) development.
  • To discuss the evolving landscape of treatments for reflux disease and NSAID-induced complications.

Summary:

  • A new generation of PPIs with rapid and sustained action is in clinical trials for reflux disease.
  • The efficacy and safety profile of PPIs make them a preferred option over declining endoscopic treatments.

Related Experiment Videos

  • For patients at risk of NSAID-induced gastro-duodenal toxicity, non-specific NSAIDs combined with PPIs remain a viable therapeutic approach.
  • High-dose antibiotics are increasingly favored for second-line Helicobacter pylori eradication.

    • Impact:

    • These advancements offer improved therapeutic options for patients with acid-related disorders.
    • The findings guide clinical practice in managing reflux disease and NSAID-related risks.
    • Future research will likely focus on optimizing PPI efficacy and safety, alongside antibiotic stewardship in H. pylori treatment.